PD-L1 as a Biomarker for Immunotherapy; Imperfect but Important

• Reflecting on the immuno-oncology Dx landscape
• Discussing challenges for integrating CDx in immuno-oncology trials
• Navigating what’s next for immunotherapy CDx?

Speakers:

Sophie Wildsmith

Executive Director, Head of PMB Immuno- Oncology (IO) Franchise

AstraZeneca